Plain-English translation of NCT05141149 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medication called PBP1510, designed to help treat advanced pancreatic cancer. Researchers want to find the safest and most effective dose of this medication, and see whether it works better when given alone or combined with a standard chemotherapy drug called gemcitabine. The trial will enroll about 80 patients.
Pancreatic cancer is difficult to treat, and many patients' cancers stop responding to standard chemotherapy. This medication targets a protein that may help cancer cells survive and spread, offering a potentially new way to fight the disease.
You likely qualify if…
You likely don't qualify if…
You will receive the study medication (PBP1510) either alone or combined with gemcitabine chemotherapy, depending on which group you're assigned to. The trial has two phases: in Phase 1, researchers gradually increase the dose to find the safest level; in Phase 2, patients receive the best dose identified in Phase 1. You will have regular clinic visits for blood tests, scans, and check-ups to monitor how you are tolerating the treatment and whether your cancer is responding.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States
Australia
Singapore
Spain